A new editorial paper was published in Oncotarget's Volume 14 on February 11, 2023, entitled, “Unlocking the potential of molecular-driven stratification for osteosarcoma treatment and prognosis.”

Over the last 40 years, the complex genetic landscape, the heterogeneity of the microenvironment and the cell plasticity of Osteosarcoma (OSA) tumors have delayed the therapeutic and prognostic stratification of patients and the introduction of new efficient treatments. 

As a direct consequence, the vast majority of trials still don’t benefit from a selection of OSA patient-based on molecular evidence before drug administration. This lack of stratification leads to difficult interpretation of outcome, especially with targeted agents such as multikinase inhibitors or anti-osteoclastic drugs.

“Meanwhile, fortunately, the accumulation of numerous sparse but converging observations from many research and clinical teams have progressively drawn a portrait of the resistant osteosarcoma that’s paved the way to new translational discoveries.”

In their new editorial, researchers Gaël Moquin-Beaudry, Maria Eugenia Marques da Costa, Nathalie Gaspar, and Antonin Marchais from Université Paris-Saclay discussed their recent study using unsupervised machine learning algorithms to classify OSA at diagnosis based on gene expression modules functionally enriched for immune microenvironment and tumor phenotypic traits.

“Recently, several important studies have described OSA molecularly at an unprecedent[ed] level of detail taking advantage of multiomics approaches and artificial intelligence [1–3].”


Read the full editorial: DOI: https://doi.org/10.18632/oncotarget.28364 

Correspondence to: Antonin Marchais - ANTONIN.MARCHAIS@gustaveroussy.fr 

Keywords: multiomics, osteosarcoma, bone sarcoma,
stratification

About Oncotarget

Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form, and then quickly released to Pubmed. On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by Medline/PubMed and PMC/PubMed.

To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us:

SoundCloud - https://soundcloud.com/oncotarget
Facebook - https://www.facebook.com/Oncotarget/
Twitter - https://twitter.com/oncotarget
Instagram - https://www.instagram.com/oncotargetjrnl/
YouTube - https://www.youtube.com/@OncotargetJournal
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/

Media Contact
MEDIA@IMPACTJOURNALS.COM
18009220957

Oncotarget

Unlocking the Potential of Molecular-Driven Stratification of Osteosarcoma

In this episode of the humanOS Radio podcast, we welcome Hannah Went, a visionary in the realm of longevity and disruptive health technologies. With a lifelong passion for breakthrough innovations that improve the human condition, Hannah's journey began at the University of Kentucky, where she earned her degree in Biology. Her early research internships in cell signaling and cell biology laid the groundwork for her career in integrative medicine.

As the former Director of Research and Content at the International Peptide Society, Hannah recognized a unique opportunity for methylation-based age diagnostics. This insight led her to found TruDiagnostic in 2020, a cutting-edge company specializing in methylation array-based diagnostics for life extension and preventive healthcare. Today, TruDiagnostic serves functional medicine providers worldwide and boasts one of the largest private epigenetic health databases, with over 75,000 patients tested.

Driven by a commitment to research, under Hannah’s leadership, TruDiagnostic has spearheaded over 30 clinical trials exploring the epigenetic methylation changes in longevity and health interventions. Additionally, she shares her wealth of knowledge through [Everything Epigenetics](https://everythingepigenetics.com/), offering valuable insights into how DNA regulation impacts health.

Here, we explore the future of longevity, the power of epigenetics, and the transformative potential of innovative healthcare technologies.

093 - humanOS Radio - Hannah Went - Measuring Biological Age

Master Your Health
https://linktr.ee/humanOS.me

Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Oncotarget is now indexed by MEDLINE, PubMed and PMC/PubMed.

Read about the Oncotarget Scientific Integrity Process: https://www.oncotarget.com/scientific_integrity/

New tracks tagged #multiomics